Page 2 - Medicines Stock Down News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medicines stock down. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medicines Stock Down Today - Breaking & Trending Today

Barclays Boosts Blueprint Medicines (NASDAQ:BPMC) Price Target to $70.00

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price target lifted by Barclays from $58.00 to $70.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has an equal weight rating on the biotechnology company’s stock. Several other equities research analysts have also commented on the company. Needham & Company LLC […] ....

United States , Christopherk Murray , Stifel Nicolaus , Jeffreyw Albers , Financial Services Group Inc , Blueprint Medicines Company Profile , Lazard Asset Management , Securities Exchange Commission , Cutler Group , Needham Company , Blueprint Medicines Corporation , Blueprint Medicines , Free Report , Moderate Buy , Medicines Stock Down , Exchange Commission , Director Jeffrey , Services Group , Asset Management , Dark Forest Capital Management , Get Free Report , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Barclays Plc ,

Revolution Medicines (NASDAQ:RVMD) Research Coverage Started at Wedbush

Analysts at Wedbush started coverage on shares of Revolution Medicines (NASDAQ:RVMD – Get Free Report) in a research note issued to investors on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $41.00 price target on the stock. Wedbush’s price target suggests a potential upside of 46.48% from the company’s current price. Several […] ....

Stifel Nicolaus , Raymond James , Marka Goldsmith , Stephen Michael Kelsey , Jpmorgan Chase Co , Revolution Medicines Inc , Pricet Rowe Associates Inc , Farallon Capital Management , Vanguard Group Inc , Securities Exchange Commission , Revolution Medicines Company Profile , Revolution Medicines , Get Free Report , Medicines Stock Down , Exchange Commission , Capital Management , Pricet Rowe Associates , Revolution Medicines Daily , Nasdaq Rvmd , Initiated Coverage ,

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. reduced its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 16.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 7,639 shares of the biotechnology company’s stock after selling 1,556 shares during the period. E Fund Management Co. Ltd.’s holdings in Blueprint Medicines were worth $483,000 at […] ....

United States , New Zealand General , New Zealand , Jeffreyw Albers , Wellington Management Group , E Fund Management Co , Blueprint Medicines Co , Securities Exchange Commission , Fund Management Co , Blueprint Medicines Company Profile , Pricet Rowe Associates Inc , Wells Fargo Company , Vanguard Group Inc , Blackrock Inc , Blueprint Medicines Corporation , Blueprint Medicines , Free Report , Fund Management , Management Group , State Street Corp , Street Corp , Director Jeffrey , Exchange Commission , Wells Fargo , Medicines Stock Down , Get Free Report ,

Revolution Medicines (NASDAQ:RVMD) Sees Strong Trading Volume

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) shares saw an uptick in trading volume on Wednesday . 922,202 shares were traded during trading, a decline of 38% from the previous session’s volume of 1,488,233 shares.The stock last traded at $21.24 and had previously closed at $20.87. Analysts Set New Price Targets Several research firms […] ....

Raymond James , Stifel Nicolaus , Margareta Horn , Barbara Weber , Needham Company , Revolution Medicines Company Profile , Barclays Plc , Monashee Investment Management , Allspring Global Investments Holdings , Jpmorgan Chase Co , Revolution Medicines Inc , York Mellon Corp , Revolution Medicines , Get Free Report , Medicines Stock Down , Director Barbara Weber , Investment Management , Global Investments Holdings , New York Mellon Corp , Revolution Medicines Daily , Nasdaq Rvmd ,

Analysts Set Blueprint Medicines Co. (NASDAQ:BPMC) Price Target at $75.08

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one […] ....

New Zealand General , New Zealand , United States , Jeffreyw Albers , Fouad Namouni , Blueprint Medicines Co , Wells Fargo Company , Morgan Stanley , Wellington Management Group , Pricet Rowe Associates Inc , Goldman Sachs Group , Norges Bank , Marshall Wace , Blueprint Medicines Corporation , Blueprint Medicines Company Profile , Blueprint Medicines , Get Free Report , Marketbeat Ratings , Medicines Stock Down , Director Jeffrey , Street Corp , Management Group , Get Free , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc ,